Vima Therapeutics, a US-based biotechnology firm, has successfully raised $40 million in a Series A extension, enhancing its total funding for this round to $100 million. This financing initiative was spearheaded by Frazier Life Sciences, with notable contributions from existing investors including Atlas Venture, Access Industries, and Canaan Partners.
The recent funding coincides with the commencement of a Phase II trial for VIM0423, an oral therapy targeting isolated dystonia, marking a significant step forward in the treatment of this movement disorder. The newly acquired capital will not only support the ongoing trial but will also facilitate the initiation of a planned Phase II trial for Parkinson’s disease, which is expected to commence in mid-2026. Preliminary results from both studies are anticipated in the first half of 2027.
VIM0423 is designed to selectively inhibit muscarinic cholinergic receptors in the brain that are implicated in dystonia, a chronic neurological disorder characterised by involuntary muscle contractions. By focusing on these specific receptors, the therapy aims to alleviate movement-related symptoms while minimising the off-target effects commonly associated with older treatment options.
For further information on funding opportunities in the biotechnology sector, please refer to resources such as the UK Research and Innovation (UKRI) and Innovate UK.